Cyendiv 100mg Capsule

About

Cyendiv 100mg Capsule, containing nintedanib, is a small molecule tyrosine kinase inhibitor that targets multiple receptors involved in fibrotic processes and tumor angiogenesis. It specifically inhibits the activity of platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1, 2, and 3, and vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. By blocking these key receptors, nintedanib interferes with crucial signaling pathways responsible for the proliferation, migration, and differentiation of fibroblasts, as well as the formation of new blood vessels. This dual mechanism of action makes it effective in treating idiopathic pulmonary fibrosis (IPF) by slowing disease progression and in certain types of non-small cell lung cancer (NSCLC) by inhibiting tumor growth.

The therapeutic benefits of Cyendiv 100mg Capsule extend to slowing the decline in lung function in patients with idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD), as well as in other chronic fibrosing interstitial lung diseases with a progressive phenotype. In oncology, it is used in combination with docetaxel for advanced NSCLC. Patients should be carefully monitored for potential side effects, particularly gastrointestinal issues and liver enzyme elevations. It is an oral medication, offering convenience for long-term management of chronic conditions.

Uses

• Idiopathic pulmonary fibrosis (IPF)
• Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
• Chronic fibrosing interstitial lung diseases with a progressive phenotype
• Non-small cell lung cancer (NSCLC) in combination with docetaxel

Directions For Use

Take orally with food, usually twice daily, as directed by your doctor. Swallow capsules whole; do not chew or crush.

Benefits

• Slows the progression of idiopathic pulmonary fibrosis.
• Reduces decline in lung function in SSc-ILD.
• Offers a treatment option for progressive fibrosing ILDs.
• Improves progression-free survival in NSCLC.
• Oral administration for convenience.
• Targets multiple pathways involved in disease.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Decreased appetite
• Weight loss
• Liver enzyme elevation
• Hypertension
• Headache
• Fatigue
• Bleeding events
• Arterial thromboembolic events

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may increase the risk of liver enzyme elevation and liver injury.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential must use highly effective contraception.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if nintedanib is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with mild hepatic impairment; contraindicated in moderate or severe hepatic impairment. Close monitoring of liver function is essential.
• Kidney - Use with caution in patients with severe renal impairment as data are limited. No dose adjustment is typically needed for mild to moderate impairment.
• Lung - Used to treat lung conditions like IPF and ILD. Monitor for worsening respiratory symptoms or new onset of pulmonary hypertension.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.